A popular over-the-counter supplement millions of older Americans take for joint pain now carries a troubling link to faster Alzheimer’s disease, according to new University of Florida research.
Story Snapshot
- University of Florida researchers found glucosamine use tied to a 25% higher chance of progressing from mild cognitive impairment to dementia.
- Lab tests on mice showed glucosamine worsened memory problems linked to Alzheimer’s-related brain damage.
- The supplement industry says the study proves nothing and left out key facts about patients’ health.
- Earlier studies on glucosamine found the opposite, including lower dementia risk in some large groups.
- Millions of Americans take glucosamine daily without a prescription or a government warning label.
University of Florida Researchers Sound the Alarm
University of Florida researchers studied electronic health records from thousands of patients with mild cognitive impairment. After controlling for age, sex, and other demographics, they found glucosamine users were 25% more likely to progress to full-blown Alzheimer’s disease. The findings appeared June 9 in the journal Nature Metabolism and quickly drew national attention from health reporters and worried patients alike.
The researchers did not stop at health records. They also ran lab experiments to test whether glucosamine actually changes brain chemistry, rather than just showing up alongside worse outcomes by coincidence. That extra step is what turned a simple statistical pattern into a genuine scientific debate.
Lab Mice Show Glucosamine May Feed Brain Damage
Scientists identified a process called hyperglycosylation, where too much sugar-like buildup attaches to proteins in the brain. In mice with Alzheimer’s-like disease, oral glucosamine made this buildup worse and hurt memory performance, while blocking the related genes improved outcomes instead. Researchers say this gives their human data a possible biological explanation, not just a coincidence in the numbers.
Separate reporting on the same study found that dementia patients who took glucosamine for at least a year faced a higher risk of death over ten years. About 8% of patients with declining brain function in the study reportedly used the supplement, underscoring how common it already is among people already fighting cognitive decline.
Supplement Makers Push Back Hard
The Natural Products Association, which represents supplement makers, rejected the study’s framing almost immediately. President and Chief Executive Officer Daniel Fabricant said there is “no conclusive evidence” glucosamine raises death risk or speeds progression to Alzheimer’s disease. He argued the health-record analysis cannot prove cause and effect and likely missed other factors driving the results.
Fabricant said the study “leaves too many unanswered questions about variables other than glucosamine supplements” and urged consumers to stay skeptical until human clinical trials confirm anything. That is a fair point for readers tired of headlines treating every single study as settled science, especially when a supplement millions rely on gets targeted overnight.
Years of Conflicting Studies Complicate the Picture
This is not the first word on glucosamine and the brain, and it will not be the last. Earlier large studies found the supplement linked to lower risk of vascular dementia and even lower overall dementia risk, with one UK Biobank analysis showing a 16% reduction in all-cause dementia among regular users. Other research found no meaningful link at all after adjusting for other health factors.
That inconsistent track record matters. Glucosamine is bought over the counter by people who differ from non-users in pain levels, overall health, and how often they see a doctor, all things retrospective studies struggle to fully account for. A study claiming a supplement helps the brain one year and harms it the next should make any reader pause before trusting the loudest headline.
What It Means for Americans Who Take the Supplement
No federal agency has issued a warning label or restriction on glucosamine, and the researchers themselves are calling for large clinical trials before drawing firm conclusions. Americans who rely on this common supplement for joint pain deserve real answers, not another government-adjacent panic cycle built on one preliminary study. Talking with a personal doctor, not a headline, remains the smartest move for anyone with memory concerns weighing this decision.
A large health-record analysis found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. Lab experiments suggest the popular joint supplement may intensify an abnormal sugar-tagging processhttps://t.co/HzxULEHn12
— Michael W. Deem (@Michael_W_Deem) September 27, 2026
Until larger, controlled human trials settle the question, this remains an open scientific debate rather than a proven danger. That distinction matters for a country increasingly skeptical of institutions rushing to declare “the science is settled” before the evidence is actually complete.
Sources:
sciencedaily.com, ufhealth.org, scholars.uky.edu, icaa.cc, nmi.health, npanational.org, peoplespharmacy.com
